Letairis is an oral tablet created by Gilead for the treatment of pulmonary arterial hypertension. The active ingredient in Letairis is ambrisentan. This drug was first approved for market use on June 15, 2007.
There are a total of 3 patents associated with Letairis, none of which have expired yet. The likelihood of a generic version of Letairis being released is expected after the expiration of the last patent on October 14, 2031. This date could also be due to a Para IV filing, which allows a generic to be released sooner in some cases.
Letairis is specifically used for the treatment of pulmonary arterial hypertension (PAH) in combination with tadalafil. The ratio of its main ingredient, ambrisentan, to Tadalafil ranges from about 1:2 to about 1:3. This combination proves effective in treating PAH.
Letairis is shielded by 3 key patents with the latest one expiring on October 14, 2031. Some of the patents include 'Method for treating a pulmonary hypertension condition' and 'Compositions and methods of treating pulmonary hypertension'. For more information on when a generic for Letairis could be available, see the patents listed below: